Oscient Pharmaceuticals About
Oscient Pharmaceuticals Oscient Pharmaceuticals Corporation is
a biopharmaceutical company committed to the clinical development and commercialization
of novel therapeutics to address unmet medical needs. The Company is marketing
its FDA-approved lead product, FACTIVE® (gemifloxacin mesylate) tablets.
In addition to the oral tablet form, Oscient Pharmaceuticals is developing a FACTIVE
intravenous formulation for hospitalized patients. The Company has a novel
antibiotic candidate, Ramoplanin, in advanced clinical development for
the treatment of Clostridium difficile-associated diarrhea (CDAD). The
Company's preclinical programs include an oral peptide deformylase (PDF) inhibitor
series, under preclinical development for community-based respiratory tract infections.
FACTIVE
TABLETS (Acute Bacterial Sinusitis) FACTIVE (gemifloxacin mesylate) tablets, indicated
for the treatment of community-acquired pneumonia of mild-to-moderate severity
and acute bacterial exacerbations of chronic bronchitis. Ramoplanin
--treatment of Clostridium
difficile-associated diarrhea (CDAD) FACTIVE -Intravenous--
Bacterial Infections Oral PDF (Peptide Deformylase Inhibitors) - Respiratory
Tract Infections